The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

They use the body's own immune system to detect and kill cancer cells "Immunotherapies have been very promising and has ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

The vast majority of people diagnosed with prostate cancer can expect to live long, full lives thanks to improved screening that catches the disease in its early and most treatable stages. But ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...